These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

177 related articles for article (PubMed ID: 21799810)

  • 1. Virosome-formulated Plasmodium falciparum AMA-1 & CSP derived peptides as malaria vaccine: randomized phase 1b trial in semi-immune adults & children.
    Cech PG; Aebi T; Abdallah MS; Mpina M; Machunda EB; Westerfeld N; Stoffel SA; Zurbriggen R; Pluschke G; Tanner M; Daubenberger C; Genton B; Abdulla S
    PLoS One; 2011; 6(7):e22273. PubMed ID: 21799810
    [TBL] [Abstract][Full Text] [Related]  

  • 2. A randomized placebo-controlled phase Ia malaria vaccine trial of two virosome-formulated synthetic peptides in healthy adult volunteers.
    Genton B; Pluschke G; Degen L; Kammer AR; Westerfeld N; Okitsu SL; Schroller S; Vounatsou P; Mueller MM; Tanner M; Zurbriggen R
    PLoS One; 2007 Oct; 2(10):e1018. PubMed ID: 17925866
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Phase 1 randomized controlled trial to evaluate the safety and immunogenicity of recombinant Pichia pastoris-expressed Plasmodium falciparum apical membrane antigen 1 (PfAMA1-FVO [25-545]) in healthy Malian adults in Bandiagara.
    Thera MA; Coulibaly D; Kone AK; Guindo AB; Traore K; Sall AH; Diarra I; Daou M; Traore IM; Tolo Y; Sissoko M; Niangaly A; Arama C; Baby M; Kouriba B; Sissoko MS; Sagara I; Toure OB; Dolo A; Diallo DA; Remarque E; Chilengi R; Noor R; Sesay S; Thomas A; Kocken CH; Faber BW; Imoukhuede EB; Leroy O; Doumbo OK
    Malar J; 2016 Aug; 15(1):442. PubMed ID: 27577237
    [TBL] [Abstract][Full Text] [Related]  

  • 4. A virosomal malaria peptide vaccine elicits a long-lasting sporozoite-inhibitory antibody response in a phase 1a clinical trial.
    Okitsu SL; Silvie O; Westerfeld N; Curcic M; Kammer AR; Mueller MS; Sauerwein RW; Robinson JA; Genton B; Mazier D; Zurbriggen R; Pluschke G
    PLoS One; 2007 Dec; 2(12):e1278. PubMed ID: 18060072
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Preclinical profiling of the immunogenicity of a two-component subunit malaria vaccine candidate based on virosome technology.
    Okitsu SL; Mueller MS; Amacker M; Vogel D; Westerfeld N; Robinson JA; Zurbriggen R; Pluschke G
    Hum Vaccin; 2008; 4(2):106-14. PubMed ID: 18382133
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Satisfactory safety and immunogenicity of MSP3 malaria vaccine candidate in Tanzanian children aged 12-24 months.
    Lusingu JP; Gesase S; Msham S; Francis F; Lemnge M; Seth M; Sembuche S; Rutta A; Minja D; Segeja MD; Bosomprah S; Cousens S; Noor R; Chilengi R; Druilhe P
    Malar J; 2009 Jul; 8():163. PubMed ID: 19607731
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Safety and immunogenicity of an AMA1 malaria vaccine in Malian children: results of a phase 1 randomized controlled trial.
    Thera MA; Doumbo OK; Coulibaly D; Laurens MB; Kone AK; Guindo AB; Traore K; Sissoko M; Diallo DA; Diarra I; Kouriba B; Daou M; Dolo A; Baby M; Sissoko MS; Sagara I; Niangaly A; Traore I; Olotu A; Godeaux O; Leach A; Dubois MC; Ballou WR; Cohen J; Thompson D; Dube T; Soisson L; Diggs CL; Takala SL; Lyke KE; House B; Lanar DE; Dutta S; Heppner DG; Plowe CV
    PLoS One; 2010 Feb; 5(2):e9041. PubMed ID: 20140214
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Safety and immunogenicity of a malaria vaccine, Plasmodium falciparum AMA-1/MSP-1 chimeric protein formulated in montanide ISA 720 in healthy adults.
    Hu J; Chen Z; Gu J; Wan M; Shen Q; Kieny MP; He J; Li Z; Zhang Q; Reed ZH; Zhu Y; Li W; Cao Y; Qu L; Cao Z; Wang Q; Liu H; Pan X; Huang X; Zhang D; Xue X; Pan W
    PLoS One; 2008 Apr; 3(4):e1952. PubMed ID: 18398475
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Phase I dose escalation safety and immunogenicity trial of Plasmodium falciparum apical membrane protein (AMA-1) FMP2.1, adjuvanted with AS02A, in malaria-naïve adults at the Walter Reed Army Institute of Research.
    Polhemus ME; Magill AJ; Cummings JF; Kester KE; Ockenhouse CF; Lanar DE; Dutta S; Barbosa A; Soisson L; Diggs CL; Robinson SA; Haynes JD; Stewart VA; Ware LA; Brando C; Krzych U; Bowden RA; Cohen JD; Dubois MC; Ofori-Anyinam O; De-Kock E; Ballou WR; Heppner DG
    Vaccine; 2007 May; 25(21):4203-12. PubMed ID: 17442466
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Phase 1/2a study of the malaria vaccine candidate apical membrane antigen-1 (AMA-1) administered in adjuvant system AS01B or AS02A.
    Spring MD; Cummings JF; Ockenhouse CF; Dutta S; Reidler R; Angov E; Bergmann-Leitner E; Stewart VA; Bittner S; Juompan L; Kortepeter MG; Nielsen R; Krzych U; Tierney E; Ware LA; Dowler M; Hermsen CC; Sauerwein RW; de Vlas SJ; Ofori-Anyinam O; Lanar DE; Williams JL; Kester KE; Tucker K; Shi M; Malkin E; Long C; Diggs CL; Soisson L; Dubois MC; Ballou WR; Cohen J; Heppner DG
    PLoS One; 2009; 4(4):e5254. PubMed ID: 19390585
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Safety and immunogenicity of a recombinant Plasmodium falciparum AMA1-DiCo malaria vaccine adjuvanted with GLA-SE or Alhydrogel® in European and African adults: A phase 1a/1b, randomized, double-blind multi-centre trial.
    Sirima SB; Durier C; Kara L; Houard S; Gansane A; Loulergue P; Bahuaud M; Benhamouda N; Nebié I; Faber B; Remarque E; Launay O;
    Vaccine; 2017 Oct; 35(45):6218-6227. PubMed ID: 28947345
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Safety and immunogenicity of an AMA-1 malaria vaccine in Malian adults: results of a phase 1 randomized controlled trial.
    Thera MA; Doumbo OK; Coulibaly D; Diallo DA; Kone AK; Guindo AB; Traore K; Dicko A; Sagara I; Sissoko MS; Baby M; Sissoko M; Diarra I; Niangaly A; Dolo A; Daou M; Diawara SI; Heppner DG; Stewart VA; Angov E; Bergmann-Leitner ES; Lanar DE; Dutta S; Soisson L; Diggs CL; Leach A; Owusu A; Dubois MC; Cohen J; Nixon JN; Gregson A; Takala SL; Lyke KE; Plowe CV
    PLoS One; 2008 Jan; 3(1):e1465. PubMed ID: 18213374
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Adenovirus 5-vectored P. falciparum vaccine expressing CSP and AMA1. Part A: safety and immunogenicity in seronegative adults.
    Sedegah M; Tamminga C; McGrath S; House B; Ganeshan H; Lejano J; Abot E; Banania GJ; Sayo R; Farooq F; Belmonte M; Manohar N; Richie NO; Wood C; Long CA; Regis D; Williams FT; Shi M; Chuang I; Spring M; Epstein JE; Mendoza-Silveiras J; Limbach K; Patterson NB; Bruder JT; Doolan DL; King CR; Soisson L; Diggs C; Carucci D; Dutta S; Hollingdale MR; Ockenhouse CF; Richie TL
    PLoS One; 2011; 6(10):e24586. PubMed ID: 22003383
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Immunogenicity of a virosomally-formulated Plasmodium falciparum GLURP-MSP3 chimeric protein-based malaria vaccine candidate in comparison to adjuvanted formulations.
    Tamborrini M; Stoffel SA; Westerfeld N; Amacker M; Theisen M; Zurbriggen R; Pluschke G
    Malar J; 2011 Dec; 10():359. PubMed ID: 22166048
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Phase 1b randomized trial and follow-up study in Uganda of the blood-stage malaria vaccine candidate BK-SE36.
    Palacpac NM; Ntege E; Yeka A; Balikagala B; Suzuki N; Shirai H; Yagi M; Ito K; Fukushima W; Hirota Y; Nsereko C; Okada T; Kanoi BN; Tetsutani K; Arisue N; Itagaki S; Tougan T; Ishii KJ; Ueda S; Egwang TG; Horii T
    PLoS One; 2013; 8(5):e64073. PubMed ID: 23724021
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Immunoglobulin G subclass and antibody avidity responses in Malian children immunized with Plasmodium falciparum apical membrane antigen 1 vaccine candidate FMP2.1/AS02
    Berry AA; Gottlieb ER; Kouriba B; Diarra I; Thera MA; Dutta S; Coulibaly D; Ouattara A; Niangaly A; Kone AK; Traore K; Tolo Y; Mishcherkin V; Soisson L; Diggs CL; Blackwelder WC; Laurens MB; Sztein MB; Doumbo OK; Plowe CV; Lyke KE
    Malar J; 2019 Jan; 18(1):13. PubMed ID: 30658710
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Safety, immunogenicity and duration of protection of the RTS,S/AS02(D) malaria vaccine: one year follow-up of a randomized controlled phase I/IIb trial.
    Aide P; Aponte JJ; Renom M; Nhampossa T; Sacarlal J; Mandomando I; Bassat Q; Manaca MN; Leach A; Lievens M; Vekemans J; Dubois MC; Loucq C; Ballou WR; Cohen J; Alonso PL
    PLoS One; 2010 Nov; 5(11):e13838. PubMed ID: 21079803
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Safety and immunogenicity of the malaria vaccine candidate MSP3 long synthetic peptide in 12-24 months-old Burkinabe children.
    Sirima SB; Tiono AB; Ouédraogo A; Diarra A; Ouédraogo AL; Yaro JB; Ouédraogo E; Gansané A; Bougouma EC; Konaté AT; Kaboré Y; Traoré A; Chilengi R; Soulama I; Luty AJ; Druilhe P; Cousens S; Nébié I
    PLoS One; 2009 Oct; 4(10):e7549. PubMed ID: 19855847
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Adenovirus-5-vectored P. falciparum vaccine expressing CSP and AMA1. Part B: safety, immunogenicity and protective efficacy of the CSP component.
    Tamminga C; Sedegah M; Regis D; Chuang I; Epstein JE; Spring M; Mendoza-Silveiras J; McGrath S; Maiolatesi S; Reyes S; Steinbeiss V; Fedders C; Smith K; House B; Ganeshan H; Lejano J; Abot E; Banania GJ; Sayo R; Farooq F; Belmonte M; Murphy J; Komisar J; Williams J; Shi M; Brambilla D; Manohar N; Richie NO; Wood C; Limbach K; Patterson NB; Bruder JT; Doolan DL; King CR; Diggs C; Soisson L; Carucci D; Levine G; Dutta S; Hollingdale MR; Ockenhouse CF; Richie TL
    PLoS One; 2011; 6(10):e25868. PubMed ID: 22003411
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Phase I Clinical Trial of a Recombinant Blood Stage Vaccine Candidate for Plasmodium falciparum Malaria Based on MSP1 and EBA175.
    Chitnis CE; Mukherjee P; Mehta S; Yazdani SS; Dhawan S; Shakri AR; Bhardwaj R; Gupta PK; Hans D; Mazumdar S; Singh B; Kumar S; Pandey G; Parulekar V; Imbault N; Shivyogi P; Godbole G; Mohan K; Leroy O; Singh K; Chauhan VS
    PLoS One; 2015; 10(4):e0117820. PubMed ID: 25927360
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.